During the first four years of this funding period, The Ohio State University Comprehensive Cancer Center (OSUCCC) has experienced growth and expansion of its Programs, primarily related to the opening of the Arthur G. James Cancer Hospital and Research Institute (CHRI) in July, 1990. The OSUCCC organization reflects importance. The OSUCCC Director also serves as the CHRI Director and oversees the CHRI administration. Of the 68 OSU interdisciplinary academic Centers, it is the only one whose director has a direct reporting relationship to the President and Board of Trustees of the University. The OSUCCC organizational model links all of the OSUCCC research Programs to the respective cancer disease sites. This reflects the OSUCCC leadership's recognition that one of its primary responsibilities involves facilitating, expanding, and expediting translational research activities. This application will describe the past accomplishments and future plans of the thirteen OSUCCC Programs which are served by thirteen OSUCCC shared services. It will also describe future plans for the next funding period which include the development of a major new Program in human cancer genetics. The request for support described in this application is a strong attempt by OSUCCC leadership to recognize its responsibility to the national community of NCI approved cancer Centers during this difficult time of budgetary constraints for support of NCI Centers. Accordingly, the budget request in this competitive renewal application for Year 21 represents a reduction in the prior year CCSG support. The total five-year requested support represents only a 17 percent increase from the prior funding period which is less than what would be expected from inflationary increases alone. This has been accomplished through utilizing non-CCSG sources of support for the OSUCCC. But it has been achieved primarily as an expression of the OSUCCC's effort to try to weigh its individual Center needs with the needs of all the other NCI approved cancer Centers and the contracted ability of the NCI budget to provide this support. The OSUCCC is proud of its past accomplishments and enthusiastically welcomes the challenges and opportunities described in this application for further expansion during the next five-year funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-24
Application #
2732954
Study Section
Cancer Center Support Review Committee (CCS)
Program Officer
Marino, Michael A
Project Start
1977-07-01
Project End
1999-11-30
Budget Start
1998-07-01
Budget End
1999-11-30
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications